Trial Profile

A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Risedronic acid
Indications Postmenopausal osteoporosis
Focus Registrational; Therapeutic Use
Sponsors Amgen

Most Recent Events

15 Jun 2013 Primary analysis presented at the 14th Annual Congress of the European League Against Rheumatism.
03 Nov 2012 Status changed from active, no longer recruiting to completed.
16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com